Patent: 10,000,565

Summary for Patent: 10,000,565

Title:	Use of IL-1 .beta. binding antibodies for treating peripheral arterial disease
Abstract:	The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1.beta. binding antibody or functional fragment thereof.
Inventor(s):	Basson; Craig (Needham, MA), Fishman; Mark (Newton Center, MA), Thuren; Tom (Succasunna, NJ), Foo; Shi Yin (Brookline, MA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	14/442,536
Patent Claims:	see list of patent claims

Executive summary

United States Patent 10,000,565 claims subcutaneous dosing regimens of an IL‑1β–binding antibody for symptomatic intermittent claudication due to peripheral arterial disease (PAD), with specific antibody sequence/epitope definitions, dose range 150–300 mg, administration intervals q1mo/q2mo/q3mo, and PAD-imaging endpoints (eg, superficial femoral artery plaque burden at ≥3 months or ≥12 months). Claim 11 narrows the antibody to canakinumab, and claim 12 narrows the formulation to a liquid composition with 10–200 mg/mL canakinumab, mannitol, histidine, polysorbate 80, and pH 6.1–6.9.

A critical read of the claim set indicates an estate built around (i) patient selection (ABI <0.9; often 0.5–0.85), (ii) dose and dosing-frequency schedules (150–300 mg; monthly/every-two-months/every-three-months), (iii) antibody definition (SEQ ID/VH-VL sequences and CDR sets), and (iv) objective vascular endpoints after defined durations. The strongest commercialization barriers are where a competitor tries to launch an IL‑1β blocker for PAD using (a) canakinumab (or an antibody with the claimed VH/VL sequences or CDRs) and (b) the same regimen and imaging endpoints.

The analysis below evaluates claim scope, likely claim construction pressure points, and how the PAD IL‑1β antibody patent landscape typically interacts with related IL‑1β antibodies, formulation patents, and regulatory/Orange Book-style exclusivity for US launches.

---

How broad are the claims of US Patent 10,000,565 for treating PAD with an IL‑1β antibody?

Core independent claim (claim 1) structure. Claim 1 is a method-of-treatment claim that combines four constraints:

1. Disease and patient phenotype

• “Peripheral arterial disease (PAD)” with symptomatic intermittent claudication
• “Ankle-brachial index less than 0.9 in at least one leg before treatment”

2. Route, dose, and frequency

• Subcutaneous administration
• dose: about 150 mg to about 300 mg
• dosing interval: every month, every two months, or every three months

3. Treatment window

• The independent claim is “administering… wherein the antibody is administered every month/every two months/every three months.” The defined time-based endpoints appear in dependent claims (3–6).

4. Antibody identity

• antibody comprises either:
  • (a) VH sequence = SEQ ID NO:1 and VL sequence = SEQ ID NO:2, or
  • (b) VH CDRs 1–3 = SEQ ID NO:3/4/5 and VL CDRs 1–3 = SEQ ID NO:6/7/8

How claim 1 limits design-around options

• A competitor cannot move to IV dosing or oral dosing without leaving “subcutaneous dose” and likely losing infringement.
• A competitor that uses a different IL‑1β antibody must still meet the sequence/CDR identity language. The CDR-only alternative can expand infringement risk if a different full-length antibody matches those CDR sequences even if framework residues differ.
• A competitor can attempt to avoid by selecting:
  • patients with ABI ≥0.9 (but claim 2 still preserves infringement if the target ABI is between 0.5 and 0.85),
  • dosing outside 150–300 mg or outside q1mo/q2mo/q3mo schedules (eg, loading doses, weekly dosing, or biologics with different interval logic),
  • endpoints not framed as plaque burden in the superficial femoral artery after the claimed durations (but note: claim 1 does not require an endpoint; dependent claims do).

---

Which IL‑1β antibodies could infringe claim 1 based on VH/VL SEQ ID and CDR sequences?

Sequence gating. Claim 1 is anchored to very specific antibody sequence definitions:

• Option (a): VH sequence SEQ ID NO:1 + VL sequence SEQ ID NO:2
• Option (b): VH CDR1-3 SEQ ID NO:3/4/5 and VL CDR1-3 SEQ ID NO:6/7/8

Practical effect: This is not a generic “any IL‑1β binder” claim. It is a sequence-defined antibody claim. That typically makes infringement hinge on:

• exact CDR matching, and/or
• exact VH/VL sequence matching across the recited regions.

Claim 11 narrows further to canakinumab. Claim 11 explicitly recites:

• “wherein said IL‑1β binding antibody is canakinumab.”

This matters in two ways:

• If a competitor uses canakinumab, it has an infringement lane for both claim 11 and the upstream general antibody definitions in claim 1 (assuming canakinumab’s sequence aligns with the SEQ ID/CDR sets).
• If a competitor uses a different IL‑1β antibody, it must match the recited SEQ ID/CDR to avoid leaving the claim.

---

What do the key dependent claims add to the infringement risk: ABI bands, imaging endpoints, and treatment duration?

Claim 2: narrower baseline severity

• “ankle-brachial index between 0.5 and 0.85”

This is a narrowing refinement on top of claim 1’s ABI <0.9. It is likely intended to map to specific PAD trial inclusion criteria or stratification groups.

Claims 3–6: vascular structure and plaque burden endpoints

• Claim 3: “improved vascular structure and function after 3 months”
• Claim 4: “reduced plaque burden… after at least 3 months”
• Claim 5: reduced plaque burden in superficial femoral artery after at least 3 months
• Claim 6: reduced plaque burden in superficial femoral artery after at least 12 months

Critical point: These are method steps that define what “reduced plaque burden… is observed” and when. If competitors position clinical programs around different biomarkers (eg, systemic inflammation markers), different vascular territories (eg, common femoral instead of superficial femoral), or different assessment timelines, they may reduce exposure to dependent claims even if the independent claim remains contested.

Claim 7: duration at least one year

• “administered for a duration of at least one year”

A competitor using only a short-course regimen (eg, <12 months) could argue non-infringement of claim 7 while still potentially infringing the earlier regimen features of claims 1 and 2.

---

How specific are the dosing claims: what happens if competitors change mg, loading, or intervals?

Claim 1 dose range and route

• subcutaneous dose: about 150 mg to about 300 mg
• administration interval: every month, every two months, or every three months

Claims 8–9: single-dose anchoring

• Claim 8: dose = about 150 mg
• Claim 9: dose = about 300 mg

Implication: If an accused regimen uses 150 mg or 300 mg, infringement risk increases because the dependent claims track exact dose points.

Design-around logic:

• Using 100 mg, 200 mg (not directly excluded by claim 1’s “about 150–300” but potentially excluded depending on claim construction of “about”), or 400 mg likely shifts the regimen outside the claimed range.
• Switching frequency to something outside q1mo/q2mo/q3mo (eg, every 10 days, every 6 weeks) avoids the express interval structure.

---

What antibody binding potency element appears in the claims, and how does it affect infringement analysis?

Claim 10 requires:

• antibody capable of inhibiting binding of IL‑1β to its receptor
• “K_D for binding to IL‑1β of about 50 pM or less”

Effect on scope:

• This adds a functional affinity threshold. A competitor with an IL‑1β binder with weaker affinity (higher K_D) may avoid claim 10 even if sequence matches.
• If the antibody is canakinumab and its K_D is consistent with that threshold, claim 10 can be a straightforward compliance element.

Litigation pressure point:

• K_D measurement depends on assay conditions. Claim construction may require how “K_D … of about 50 pM or less” is interpreted and whether a party can choose assays to create non-infringing outcomes.

---

What is the canakinumab-specific formulation scope in claim 12, and how does it change infringement exposure?

Claim 12 narrows to a liquid formulation comprising:

• 10–200 mg/mL canakinumab
• mannitol
• histidine
• polysorbate 80
• pH 6.1–6.9

This is a classic “formulation-by-composition” dependent claim. A competitor who uses canakinumab but with a different excipient system, buffer system, polysorbate type/concentration, or pH outside the range reduces risk for claim 12 while still potentially exposing to claims 1 and 11 (which do not require this formulation).

Claim 13 further ties to presentation:

• provided in liquid form for administration in a prefilled syringe or
• lyophilized form for reconstitution in a prefilled syringe.

If an accused product uses different packaging (eg, multi-dose vial, cartridge system), it may avoid claim 13.

---

What comedications are implicated in dependent claim 14 and claim 15, and are they likely material to infringement?

• Claim 14: concomitantly receiving a statin
• Claim 15: concomitantly receiving a beta-adrenergic blocker, an ACE inhibitor, or an angiotensin II receptor blocker

These are patient-background features. In practice:

• If a PAD prescriber routinely uses these comedications, the claim may be easier to meet factually.
• A competitor may not be able to “control” real-world concomitant therapy in a way that reliably avoids infringement.

---

How does US 10,000,565 likely fit into a broader IL‑1β PAD patent estate?

Even without the rest of the referenced US publication file, the structure of the claims indicates typical estate layering:

1. Antibody identity claims

• Sequence/CDR-defined antibody claims (claim 1 and 11)

2. Clinical method claims

• Patient phenotype (ABI thresholds)
• Dosing regimen (mg range and interval)
• Duration (≥1 year)
• Endpoints (superficial femoral artery plaque burden at ≥3 and ≥12 months)

3. Formulation and presentation claims

• Specific liquid composition and pH (claim 12)
• Form factor (prefilled syringe; lyophilized for reconstitution; claim 13)

Critical reading: The presence of both sequence-defined antibody definitions and canakinumab-specific dependent claims indicates the applicant wanted coverage for:

• the exact blockbuster antibody (canakinumab) and
• any close variants matching the recited SEQ ID/CDRs.

That combination typically supports a litigation posture where a claimant can argue “core antibody identity” through either full VH/VL sequences or CDR sets.

---

When does US 10,000,565 lose exclusivity, and how does that map to PAD clinical trial timelines?

No expiration data (filing date, nonprovisional date, PTA/PT adjustments, or patent term adjustments) is provided in the prompt. Without filing and term information, an exclusivity timeline cannot be calculated accurately.

---

What generic or biosimilar entry risks exist for PAD IL‑1β therapy once 10,000,565 is challenged?

Generic “IL‑1β blocker” risk

• If canakinumab is the active antibody, a non-biologic generic pathway is not available; entry is through biosimilars or follow-on biologics.

Biosimilar pathway and claim exposure

• Sequence-defined antibody claims raise biosimilar comparison risk. A biosimilar manufacturer typically seeks a totality approach to prove non-infringement by showing differences in amino-acid sequences in the claimed regions. If the claim is CDR-based, the comparison must address whether the biosimilar matches those CDR sequences.

Switching therapy as a non-infringing route

A sponsor can reduce infringement risk by:

• using a different IL‑1β binder whose VH/VL sequences do not match the recited SEQ IDs or whose CDR sequences differ, or
• using different dosing schedules outside the monthly/two-monthly/three-monthly structure, or
• avoiding the specified ABI criteria and/or the same plaque-burden endpoint framing in later-dependent claims.

---

What patent litigation issues are likely to arise from the claim language?

1) Sequence/CDR identity proof disputes

• Parties will fight over what counts as “comprising” SEQ IDs and whether substitutions in frameworks matter to the claim language. Claim 1 is defined tightly, but infringement always turns on molecular comparison and expert work.

2) “About” in dose and K_D constraints

• “About 150 mg to about 300 mg” and “K_D … about 50 pM or less” are flexible terms that become battleground issues in claim construction.

3) Endpoint-dependent method claims

• Dependent claims that require observation of reduced plaque burden at defined time points can create evidentiary friction: what imaging modality, what analysis method, and what constitutes “superficial femoral artery” plaque burden measurement.

4) Concomitant medication facts

• Claims 14 and 15 depend on patient background medication. In litigation, that becomes a medical-record and billing-record discovery exercise.

---

Key Takeaways

• US 10,000,565 is a sequence-defined IL‑1β antibody PAD method patent built around subcutaneous dosing of 150–300 mg at monthly/2-month/3-month intervals.
• Claims 11–13 narrow to canakinumab and to a specific liquid formulation (mannitol, histidine, polysorbate 80; pH 6.1–6.9) and administration format.
• The dependent claims materially add ABI banding (0.5–0.85), time-based vascular endpoints (≥3 months and ≥12 months), and duration ≥1 year, plus comedication features.
• In commercial terms, design-around is most feasible by changing (i) antibody identity so that VH/VL sequences or recited CDR sequences do not match, (ii) dosing outside the claimed mg/interval structure, and/or (iii) endpoint strategy and measurement territory for dependent claims.

---

FAQs

1. Does claim 1 cover any IL‑1β antibody, or only those matching the recited SEQ IDs/CDRs?
   It is limited to antibodies whose VH/VL sequences match the recited SEQ IDs or whose VH and VL CDRs match the recited CDR sequence SEQ IDs.

2. If a product uses canakinumab but a different buffer system pH than 6.1–6.9, does it still risk infringement?
   It reduces risk for claim 12 but does not automatically eliminate risk for claims 1 and 11.

3. How can a PAD therapy avoid infringement of the dependent claims tied to superficial femoral artery plaque burden?
   Use a different clinical endpoint/measurement territory or avoid timing that satisfies the dependent claim’s observation windows (≥3 months and/or ≥12 months) and the superficial femoral artery framing.

4. Is avoiding concomitant statin/ACE inhibitor use a practical design-around?
   It can reduce likelihood of meeting dependent claims 14–15, but real-world prescribing often includes these drug classes, making complete avoidance difficult.

5. Do biosimilars face higher risk than new IL‑1β molecules under this claim set?
   Sequence/CDR-defined antibody claims can create heightened comparison exposure for biosimilars whose engineered sequences are optimized to match the reference antibody’s binding sites.

---

References (APA)

No source documents were provided in the prompt beyond the claim text of US 10,000,565, and no bibliographic details (publication number, assignee, filing date, prosecution documents, or litigation dockets) were included to support additional citations.

Details for Patent 10,000,565

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	June 17, 2009		2033-11-14
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	Injection	125319	December 22, 2016		2033-11-14